アミノ酸残留駆動ナノ粒子のタンパク質空洞の標的化:表面化学は,サイズ補完を超えた結合特異性を規定する
Fangfang Liu1,2, Guofang Zhang1,2, Xiaofeng Wang1,2
1Laboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518055 Shenzhen, China.
Journal of the American Chemical Society
|January 7, 2026
まとめ
ナノ粒子 (NP) は,以前は薬が効かないと考えられていたタンパク質の穴をターゲットにすることができます. 酸化セリウムNP (CeO2NPs) と黄金NP (AuNPs) は,SARS-CoV-2のスパイクトリマーに異なった結合をしており,選択的なNP結合の残留レベル認識を明らかにしている.
科学分野:
- バイオ物理学
- ナノテクノロジー
- ウイルス学
背景:
- タンパク質とタンパク質の相互作用のインターフェースは,大きな穴または浅い穴を持つことが,小分子薬のターゲットである.
- ナノ粒子 (NP) はこれらの"薬効性のない"部位を標的とする可能性を秘めています
- SARS-CoV-2のスパイク (S) タンパク質トリマーは,NPの相互作用に適したアクセス可能な穴を提示します.
研究 の 目的:
- タンパク質の穴のナノ粒子の標的を定める要因を調査する.
- セリウム酸化ナノ粒子 (CeO2NPs) と金ナノ粒子 (AuNPs) の結合選択性とメカニズムをSARS-CoV-2 Sトリマーと比較する.
- NPの表面化学が,アクセス可能な空洞内の特定のタンパク質残留物との相互作用にどのように影響するか解明する.
主な方法:
- 比較分析のためにサイズマッチしたCeO2NPと金ナノ粒子 (AuNP) を利用した.
- SトリマーへのNP結合を評価するために,バイオレイヤインターフェロメトリを用いた.
- 中央と横のSトリマー腔内での残留レベルでのNPタンパク質の相互作用を調査した.
主要な成果:
- CeO2NPとAuNPは,Sトリマーに結合しているが,結合プロフィールは異なる.
- CeO2NPは受容体結合領域 (RBD) 中央腔を選択的に標的とし,Asp残留物と相互作用した.
- AuNPsは,S1/S2割れ場所を含む,Argに富んだモチーフと相互作用する側腔を優先的に結合します.
結論:
- ナノ粒子のタンパク質結合は サイズ互換性ではなく 残留レベルでの認識によって決まります
- CeO2NPは,安定した結合のためにAsp残留物との調整を使用し,AuNPはArg残留物との静電吸引を使用する.
- この理解により,治療目的でタンパク質の特性を選択的に標的にするためのナノ粒子の合理的な設計が可能になります.
関連する概念動画
Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Conserved Binding Sites
5.0K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
5.0K
Protein-protein Interfaces
14.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.4K
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Factors Affecting Protein-Drug Binding: Drug-Related Factors
451
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
451


